Newsflow relating to Covid 19 vaccinations is plentiful, but what of potential treatments in the form of oral medication?
Nasdaq-listed RedHill Biopharma (NASDAQ:RDHL) is involved in that search. As chief business officer Guy Goldberg explains to Proactive London's Sarah Lowther the company is confident it may soon have a new weapon in the fight against the pandemic.
The biopharmaceutical company has completed the enrollment of its oral Opaganib phase 2/3 COVID-19 Study. The primary endpoint of the study, says RedHill, is the proportion of patients breathing room air without oxygen support by Day 14.